Skip to main content

Table 2 Characteristics of epirubicin-treated patients by UGT2B7His268Tyrgenotype

From: Impact of UGT2B7 His268Tyr polymorphism on the outcome of adjuvant epirubicin treatment in breast cancer

UGT2B7268 Genotype

Tyr/Tyr

His/Tyr + His/His

P

Number (%)

66 (32.2%)

139 (67.8%)

 

Age in years (mean, SD)

50.1 (10.7)

54.4 (10.2)

0.01

Tumor size

  

0.12

   ≤ T1 (≤ 20 mm)

29 (43.9%)

46 (33.1%)

 

   ≥ T2

35 (53.0%)

92 (66.2%)

 

   unknown

2 (3.0%)

1 (0.7%)

 

Lymph nodes

  

0.73

   0

12 (18.2%)

20 (14.4%)

 

   ≥ 1

50 (75.8%)

112 (80.6%)

 

   unknown

4 (6.1%)

7 (5.0%)

 

Grade

  

0.62

   1

1 (1.5%)

2 (1.4%)

 

   2

17 (25.8%)

46 (33.1%)

 

   > 2

43 (65.2%)

85 (61.2%)

 

   Unknown

5 (7.6%)

6 (4.3%)

 
  1. SD, standard deviation